LTR Pharma’s SPONTAN® Revolutionizes ED Treatment

LTR Pharma Limited (AU:LTP) has released an update.

LTR Pharma Limited’s new nasal spray SPONTAN® has shown promising results in a pivotal clinical study for erectile dysfunction treatment, absorbing 470% faster than oral tablets and offering a 155.6% higher peak concentration at half the dose. With a comparable bioavailability and safety profile, SPONTAN® is poised to be a market disruptor by providing patients with a more spontaneous and convenient option. The study’s outcomes are expected to strengthen LTR Pharma’s global commercialization and regulatory strategies.

For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.